Results 181 to 190 of about 131,738 (301)

We ought to discuss the social construction of cadavers: Here's why and how

open access: yes
Anatomical Sciences Education, EarlyView.
Fatima Ehsan, Susan Lamb
wiley   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden   +3 more
wiley   +1 more source

Tsunagu: Linking Lesson Study Past and Present to a Powerful Future [PDF]

open access: yes
In this interactive keynote, we will explore lesson study’s past, to understand how it helped educators navigate moments of enormous change, often brought about by international contact.
Clivaz, Stéphane, Lewis, Catherine
core  

Smartphone CBT engagement and depressive symptoms: secondary analysis of the RESiLIENT trial using a time-varying exposure approach. [PDF]

open access: yesPsychol Med
Luo Y   +8 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double‐blind randomized clinical trial in patients with mild to moderate atopic dermatitis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Recovering dysbiosis may improve atopic dermatitis (AD) symptoms. XZ.700 is a recombinant chimeric endolysin that specifically targets Staphylococcus aureus and could be a new treatment option for patients with AD. The aim of this first‐in‐human study was to evaluate the safety, tolerability and efficacy of topical XZ.700 and explore the ...
Laura W. J. van der Meulen   +13 more
wiley   +1 more source

Pulse Discovery Toolkit, a Multicomponent Nutrition Intervention for Preschool Children in Childcare Centers: Mixed Methods Pilot Study. [PDF]

open access: yesInteract J Med Res
Haileslassie HA   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy